Cem Sulu , Ayyuce Begum Bektas , Suleyman Sami Guzel , Kubilay Tay , Serdar Sahin , Emre Durcan , Hande Mefkure Ozkaya , Pinar Kadioglu
{"title":"二甲双胍对肢端肥大患者甲状腺癌风险的影响:一项初步观察研究","authors":"Cem Sulu , Ayyuce Begum Bektas , Suleyman Sami Guzel , Kubilay Tay , Serdar Sahin , Emre Durcan , Hande Mefkure Ozkaya , Pinar Kadioglu","doi":"10.1016/j.ghir.2022.101484","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the role of metformin<span><span> on thyroid cancer risk </span>in patients<span> with acromegaly.</span></span></p></div><div><h3>Methods</h3><p>Medical charts of 534 patients with acromegaly that were followed-up between 1983 and 2019 were reviewed. Patients with follow-up duration at least 6 months were included. Cohort entry was defined as first visit date. The date of each case's thyroid cancer diagnosis was defined as index date. Patients were followed until the index date, death, or last visit date, whichever came first. Nested case-control study design was selected to evaluate the association between metformin and the thyroid cancer risk in patients with acromegaly.</p></div><div><h3>Results</h3><p>291 patients with acromegaly were included into final analysis. The mean age at acromegaly diagnosis was 42.3 ± 1.3 years. The median follow-up duration was 76 [34–132] months. Among 291 patients, 13 patients (4.5%) had thyroid cancer. Thirty-one percent (<em>n</em> = 92) of the patients used metformin for 6 months or longer. One standard deviation (SD) increase in average growth hormone increased the odds of having thyroid cancer by 1.164 folds (<em>p</em> = 0.017). One SD increase of the average insulin-like growth factor 1 to upper limit of normal ratio increased the odds of having thyroid cancer by 1.201 folds (<em>p</em> = 0.004). If a patient used metformin for at least 6 months, the odds to have thyroid cancer was decreased, multiplied by 0.62 with a 95% confidence interval of [0.47, 0.83] (<em>p</em> = 0.0013). The risk of thyroid cancer decreased with increasing duration of metformin use.</p></div><div><h3>Conclusion</h3><p>Metformin may decrease the thyroid cancer risk in patients with acromegaly.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101484"},"PeriodicalIF":1.6000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study\",\"authors\":\"Cem Sulu , Ayyuce Begum Bektas , Suleyman Sami Guzel , Kubilay Tay , Serdar Sahin , Emre Durcan , Hande Mefkure Ozkaya , Pinar Kadioglu\",\"doi\":\"10.1016/j.ghir.2022.101484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>To evaluate the role of metformin<span><span> on thyroid cancer risk </span>in patients<span> with acromegaly.</span></span></p></div><div><h3>Methods</h3><p>Medical charts of 534 patients with acromegaly that were followed-up between 1983 and 2019 were reviewed. Patients with follow-up duration at least 6 months were included. Cohort entry was defined as first visit date. The date of each case's thyroid cancer diagnosis was defined as index date. Patients were followed until the index date, death, or last visit date, whichever came first. Nested case-control study design was selected to evaluate the association between metformin and the thyroid cancer risk in patients with acromegaly.</p></div><div><h3>Results</h3><p>291 patients with acromegaly were included into final analysis. The mean age at acromegaly diagnosis was 42.3 ± 1.3 years. The median follow-up duration was 76 [34–132] months. Among 291 patients, 13 patients (4.5%) had thyroid cancer. Thirty-one percent (<em>n</em> = 92) of the patients used metformin for 6 months or longer. One standard deviation (SD) increase in average growth hormone increased the odds of having thyroid cancer by 1.164 folds (<em>p</em> = 0.017). One SD increase of the average insulin-like growth factor 1 to upper limit of normal ratio increased the odds of having thyroid cancer by 1.201 folds (<em>p</em> = 0.004). If a patient used metformin for at least 6 months, the odds to have thyroid cancer was decreased, multiplied by 0.62 with a 95% confidence interval of [0.47, 0.83] (<em>p</em> = 0.0013). The risk of thyroid cancer decreased with increasing duration of metformin use.</p></div><div><h3>Conclusion</h3><p>Metformin may decrease the thyroid cancer risk in patients with acromegaly.</p></div>\",\"PeriodicalId\":12803,\"journal\":{\"name\":\"Growth Hormone & Igf Research\",\"volume\":\"66 \",\"pages\":\"Article 101484\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Growth Hormone & Igf Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1096637422000417\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096637422000417","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study
Purpose
To evaluate the role of metformin on thyroid cancer risk in patients with acromegaly.
Methods
Medical charts of 534 patients with acromegaly that were followed-up between 1983 and 2019 were reviewed. Patients with follow-up duration at least 6 months were included. Cohort entry was defined as first visit date. The date of each case's thyroid cancer diagnosis was defined as index date. Patients were followed until the index date, death, or last visit date, whichever came first. Nested case-control study design was selected to evaluate the association between metformin and the thyroid cancer risk in patients with acromegaly.
Results
291 patients with acromegaly were included into final analysis. The mean age at acromegaly diagnosis was 42.3 ± 1.3 years. The median follow-up duration was 76 [34–132] months. Among 291 patients, 13 patients (4.5%) had thyroid cancer. Thirty-one percent (n = 92) of the patients used metformin for 6 months or longer. One standard deviation (SD) increase in average growth hormone increased the odds of having thyroid cancer by 1.164 folds (p = 0.017). One SD increase of the average insulin-like growth factor 1 to upper limit of normal ratio increased the odds of having thyroid cancer by 1.201 folds (p = 0.004). If a patient used metformin for at least 6 months, the odds to have thyroid cancer was decreased, multiplied by 0.62 with a 95% confidence interval of [0.47, 0.83] (p = 0.0013). The risk of thyroid cancer decreased with increasing duration of metformin use.
Conclusion
Metformin may decrease the thyroid cancer risk in patients with acromegaly.
期刊介绍：
Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
